Volume 11, Number 1, January 2005

Distribution and Characteristics of Escherichia coli Clonal Group A

James R. Johnson,*† Andrew C. Murray,*† Michael A. Kuskowski, *† Sören Schubert,‡ Marie-Francoise Prère,§ Bertrand Picard,¶ Raul Colodner,# Raul Raz,#** and the Trans-Global Initiative for Antimicrobial Resistance Analysis (TIARA) Investigators
*VA Medical Center, Minneapolis, Minnesota, USA; †University of Minnesota, Minneapolis, Minnesota, USA; ‡Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, München, Germany; §Centre Hospitalier Universitaire Purpan, Toulouse, France; ¶Hôpital Morvan, Brest, France; #HaEmek Medical Center, Afula, Israel; and **Technion School of Medicine, Afula, Israel

Figure 2. Virulence traits (top) and antimicrobial resistance phenotypes (bottom) of Escherichia coli clonal group A (CGA) isolates versus non-CGA controls. Percentage of isolates positive for each virulence trait (top) or resistance phenotype (bottom) is shown by pink bars to left of midline (for CGA) or blue bars to right of midline (for controls). No isolates were positive for bmaE (M fimbriae), or resistant to amikacin, aztreonam, cefepime, ceftazidime, ertapenem, imipenem-cilistatin, nitrofurantoin, piperacillin-tazobactam, or ticarcillin-clavulanate. p value symbols at right of each chart, from Fisher exact or χ² test, are for significant differences between CGA and non-CGA isolates. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed December 22, 2004

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention